Navigation Links
New drug agent knocks out multiple enzymes in cancer pathway
Date:3/25/2009

A team of 24 researchers from the U.S., Europe, Taiwan and Japan and led by University of Illinois scientists has engineered a new anti-cancer agent that is about 200 times more active in killing tumor cells than similar drugs used in recent clinical trials.

The study appears this week in the Journal of the American Chemical Society.

The new agent belongs to a class of drugs called bisphosphonates. These compounds were originally developed to treat osteoporosis and other bone diseases, but were recently found to also have potent anti-cancer and immune boosting properties.

Drug developers have tried for years to design drugs to inhibit cell survival pathways in tumor cells, focusing on a protein called Ras since nearly a third of all human cancers involve a mutation in the Ras gene that causes cell signaling to go awry. These efforts have met with limited success.

Bisphosphonates act on other enzymes, called FPPS and GGPPS, which are upstream of Ras in the cell survival pathway. Inhibiting these enzymes appears to be a more effective strategy for killing cancer cells.

When used in combination with hormone therapy in a recent clinical trial, the bisphosphonate drug zoledronate significantly reduced the recurrence of breast cancer in premenopausal women with estrogen-receptor-positive breast cancer. Similar results were reported previously for hormone-refractory prostate cancer.

But zoledronate quickly binds to bone, reducing its efficacy in other tissues.

"We're trying to develop bisphosphonates that will be very active but won't bind to the bone, because if they bind to the bone they're not going to go to breast, lung or other tissues," said University of Illinois chemistry professor Eric Oldfield, who led the new study.

Oldfield's team also wanted to design a compound that would inhibit multiple enzymes in the tumor cell survival pathway, rather than just one, an approach analogous
'/>"/>

Contact: Diana Yates
diya@illinois.edu
217-333-5802
University of Illinois at Urbana-Champaign
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Structure of enzyme against chemical warfare agents determined
2. Chemopreventive agents in black raspberries identified
3. MIT nanotubes sniff out cancer agents in living cells
4. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
5. Certain anticancer agents could be harmful to patients with heart disease
6. UF researchers develop improved gene therapy agent
7. New insights into the diversity of Creutzfeldt-Jakob disease agents
8. Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports
9. Contrast agent trials in swine
10. Agent that triggers immune response in plants is uncovered
11. Primate behavior explained by computer agents
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New drug agent knocks out multiple enzymes in cancer pathway
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... is participating in a large-scale, multi-center clinical trial in ... substance, in high doses, can slow the progression of ... million people in the United States. "At present, ... only mask the symptoms they do not alter ...
... have found the "Rosetta Stone" of supervolcanoes, those giant ... massive explosive eruptions that rank among nature,s most violent ... and possibly trigger climatic and environmental effects at ... discovered in the Italian Alps, Sesia Valley by a ...
... 100 billion (1011) neurons, which altogether form about 100 ... mechanism for the generation of this complex wiring pattern ... Hannes Schmidt and Professor Fritz G. Rathjen at the ... have now discovered a molecule that regulates this vital ...
Cached Biology News:Can an over-the-counter vitamin-like substance slow the progression of Parkinson's disease? 2'Rosetta Stone' of supervolcanoes discovered in Italian Alps 2'Rosetta Stone' of supervolcanoes discovered in Italian Alps 3MDC researchers discover molecule responsible for axonal branching 2
(Date:7/28/2015)... 28, 2015 BioStructures, LLC, a privately ... a milestone of 4,000 implantations of Signafuse® Bioactive ... in early 2014 as a bone void filler ... procedures.  This is a distinguished status among recently ... of new synthetic products have received clearance with ...
(Date:7/28/2015)... July 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... it has granted to German life sciences entrepreneurs ... and commercialization of biotechnology (collectively, the "Optionee"), an ... allogenic tumor vaccine technology (the "Technology"), including AEZS-120, ... which is ready to enter a Phase 1 ...
(Date:7/28/2015)... Israel , July 28, 2015 /PRNewswire/ ... regenerative medicine company utilizing its proprietary plant-based rhCollagen ... Shomrat Shurtz has been appointed Senior Director of ...      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) , ... experience in marketing, regulatory and business strategy. Prior ...
(Date:7/27/2015)... 27, 2015  Amgen (NASDAQ: AMGN ) today ... results on Thursday, July 30, 2015, after the close ... followed by a conference call with the investment community ... Amgen will be Robert A. Bradway , chairman ... senior management team. Live audio of the ...
Breaking Biology Technology:Revolutionary Bone Graft Exceeds Expectations 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
... 31 Revotar,Biopharmaceuticals AG., today announced first positive ... pilot study in 14 patients with,stable COPD stage ... of Bimosiamose,twice a day. The study was conducted ... Witt and the Respiratory Institute Wiesbaden, Dr.,Beeh. The ...
... Oct. 31 Amedica Corporation,an orthopedic implants company ... the U.S. Food and Drug Administration,has granted 510(k) ... The Valeo(TM) Cervical Plate system combines features aimed ... The,Valeo(TM) Cervical Plate system is intended for anterior ...
... Md., Oct. 31 Micromet, Inc.,(Nasdaq: MITI ... of,novel, proprietary antibody-based products for cancer, inflammation and,autoimmune ... and,Chief Executive Officer of Micromet, will present at ... Conference in New York, on,Wednesday, November 7, 2007 ...
Cached Biology Technology:Revotar Reports First Positive Clinical Results From Phase IIa Study in COPD 2Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007 2
... Source rat adult and fetal ... $550.00, * T75 plated cells ... * This product requires Celprogen ... M55007-08 and extracellular matrix, * ...
... is a K-12 strain ideally suited as ... high transformation efficiency, blue/white screening capability (with ... result in high yields of excellent quality ... is potentially useful as a stringent host ...
... Purification with an Affinity Chitin-binding Tag) utilizes ... splicing elements (termed inteins) to purify recombinant ... (Figures 1 and 2). This system distinguishes ... its ability to separate a recombinant protein ...
... imaging system from Molecular Devices ... system for automated acquisition and analysis ... screening. ImageXpressULTRA is powered by ... screening acquisition, image storage and analysis. ...
Biology Products: